Cohort profile: Nordic Helicobacter Pylori eradication project (NordHePEP)
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Cohort profile : Nordic Helicobacter Pylori eradication project (NordHePEP). / Pettersson, Anna Klara; Santoni, Giola; Yan, Jacinth; Radkiewicz, Cecilia; Xie, Shaohua; Birgisson, Helgi; Ness-Jensen, Eivind; von Euler-Chelpin, My; Kauppila, Joonas H.; Lagergren, Jesper.
I: Scandinavian Journal of Gastroenterology, Bind 58, Nr. 5, 2023, s. 453-459.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cohort profile
T2 - Nordic Helicobacter Pylori eradication project (NordHePEP)
AU - Pettersson, Anna Klara
AU - Santoni, Giola
AU - Yan, Jacinth
AU - Radkiewicz, Cecilia
AU - Xie, Shaohua
AU - Birgisson, Helgi
AU - Ness-Jensen, Eivind
AU - von Euler-Chelpin, My
AU - Kauppila, Joonas H.
AU - Lagergren, Jesper
N1 - Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Purpose: This cohort description presents the Nordic Helicobacter Pylori Eradication Project (NordHePEP), a population-based cohort of patients having received eradication treatment for Helicobacter pylori (HP). The cohort is created with the main purpose of examining whether and to what extent HP eradication treatment influences the risk of gastrointestinal cancer. Participants: NordHePEP includes all adults (aged ≥18 years) having been prescribed and dispensed HP eradication treatment according to the nationwide complete drug registries in any of the five Nordic countries (Denmark, Finland, Iceland, Norway, or Sweden) between 1994 and 2020 (start and end year varies between countries). We have retrieved and merged individual-level data from multiple national registries, including drug, patient, cancer, population, and death registries. Findings: The cohort includes 674,771 patients having received HP eradication treatment. During up to 23 years of follow-up, 59,292 (8.8%) participants were diagnosed with cancer (non-melanoma skin cancer excluded), whereof 15,496 (2.3%) in the gastrointestinal tract. Future plans: We will analyse HP eradication treatment in relation to gastrointestinal cancer risk. Standardised incidence ratios will be calculated as the observed cancer incidence in the cohort divided by the expected cancer incidence, derived from the background population of the corresponding age, sex, and calendar year.
AB - Purpose: This cohort description presents the Nordic Helicobacter Pylori Eradication Project (NordHePEP), a population-based cohort of patients having received eradication treatment for Helicobacter pylori (HP). The cohort is created with the main purpose of examining whether and to what extent HP eradication treatment influences the risk of gastrointestinal cancer. Participants: NordHePEP includes all adults (aged ≥18 years) having been prescribed and dispensed HP eradication treatment according to the nationwide complete drug registries in any of the five Nordic countries (Denmark, Finland, Iceland, Norway, or Sweden) between 1994 and 2020 (start and end year varies between countries). We have retrieved and merged individual-level data from multiple national registries, including drug, patient, cancer, population, and death registries. Findings: The cohort includes 674,771 patients having received HP eradication treatment. During up to 23 years of follow-up, 59,292 (8.8%) participants were diagnosed with cancer (non-melanoma skin cancer excluded), whereof 15,496 (2.3%) in the gastrointestinal tract. Future plans: We will analyse HP eradication treatment in relation to gastrointestinal cancer risk. Standardised incidence ratios will be calculated as the observed cancer incidence in the cohort divided by the expected cancer incidence, derived from the background population of the corresponding age, sex, and calendar year.
KW - gastrointestinal cancer
KW - Helicobacter pylori
KW - helicobacter pylori eradication
KW - multi-national
KW - outcomes
KW - population-based
KW - Scandinavia
U2 - 10.1080/00365521.2022.2144435
DO - 10.1080/00365521.2022.2144435
M3 - Journal article
C2 - 36369751
AN - SCOPUS:85142150387
VL - 58
SP - 453
EP - 459
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - 5
ER -
ID: 343043308